Navigation Links
Monash scientists debug superbug
Date:3/2/2009

An international team of scientists, led by Monash University researchers, has uncovered the workings of a superbug that kills elderly hospital patients worldwide - a discovery that has the potential to save lives and health care systems billions of dollars each year.

The research published today in the prestigious scientific journal Nature, unravelled ways to genetically modify the bacterium Clostridium difficile and solved the mystery surrounding its toxicity.

Professor Julian Rood from the Department of Microbiology and lead author, microbiologist Dr Dena Lyras, made a major scientific breakthrough which allowed mutants of the superbug to be made. They then identified which of two suspected toxic proteins was essential for the bacterium to cause severe disease.

"Contrary to previously accepted scientific belief, our results show that toxin B, which was considered the less important toxin is actually the toxin that causes disease," Professor Rood said.

"This discovery will lead to new methods for the control and prevention of this disease".

Professor Rood and Dr Lyras have been working toward this result for more than a decade. Dr Lyras said strains of Clostridium difficile are found in almost every hospital in Australia.

"It is the major cause of diarrhoea in hospital patients undergoing antibiotic therapy. The antibiotics destroy the 'good' bacteria in the gut, allowing a 'bad' bacterium to grow in the colon, where it causes a chronic bowel infection that is very difficult to treat," Dr Lyras said.

"The disease produces two types of Toxins, known as A and B. Worldwide research has tended to focus on these purified toxins in isolation from the bug. This only resulted in part of the story being told. We took a big picture approach and through genetic modification of the bug, together with infection studies with our US collaborators, we were able to see the whole picture," Dr Lyras said.

Statistics show that in the US, more people die from Clostridium difficile infections than all other intestinal infections combined, with most deaths involving patients aged 65 years or over. The disease is believed to have contributed to more than 8,000 deaths in the UK in 2007. A less aggressive form of the bacteria is present in Australia but statistics in 1995-dollars show the cost of managing the disease to be around $1.25 million dollars per hospital, per year.

Their research lays the foundation to find better ways to treat the superbug.

"We are now beginning to understand the workings of the superbug, which allows us to work on treatments for it. We are confident our research will pave the way for future drugs to try to wipe out this disease. I can't put a time frame on how quickly drugs could be developed, but we're certainly on that road to discovery," Dr Lyras said.


'/>"/>

Contact: Dr. Dena Lyras
61-424-378-958
Monash University
Source:Eurekalert

Related biology news :

1. Monash researcher receives prestigious Commonwealth Health Ministers award
2. Monash researchers uncover cancer survival secrets
3. Killer carbs -- Monash scientist finds the key to overeating as we age
4. UK scientists working to help cut ID theft
5. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
6. Comet probes reveal evidence of origin of life, scientists claim
7. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
8. Male elephants get photo IDs from scientists
9. Scientists retrace evolution with first atomic structure of an ancient protein
10. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
11. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
Breaking Biology Technology: